The Apex Times
Above the Noise
Business Wire
BusinessAMD edges into a niche AI-networking layer as new GPU transport work targets efficiencyThe Apex TimesBusinessBefore AMD’s 137% surge, market focus shifted to AI accelerator demand and the MI450 launch narrativeThe Apex TimesBusinessAMD’s Q3 2026 Earnings Set for Early Next Month, With Analysts Looking for Double-Digit Bottom-Line GrowthThe Apex TimesBusinessBYD versus Tesla: A stock comparison that goes beyond electric-vehicle salesThe Apex TimesBusinessWall Street Sells Off as S&P 500 and Nasdaq Slip Below Key Levels, Turning Meta Earnings Into a Test for AI StocksThe Apex TimesBusinessAlphabet shares draw attention as Google and Unity move toward AI-powered game creationThe Apex TimesBusinessElon Musk Praises Jensen Huang as SpaceX and NVIDIA Push AI Data Centers for SpaceThe Apex TimesBusinessBroadcom’s AI XPUs become a focal point as investors weigh the company’s growth outlookThe Apex TimesBusinessMeta’s “Second Act” Pitch Gains Steam as Investors Focus on Muse and AI MomentumThe Apex TimesBusinessNetflix trims about 6% of staff, cutting roughly 1,000 jobs in biggest layoff round in four yearsThe Apex TimesBusinessNorthrop Grumman’s LITEF unit signs long-term inertial reference systems deal for Vertical Aerospace’s Valo eVTOLThe Apex TimesBusinessGeneral Dynamics investors weigh valuation questions as CEO succession talk reshapes attention on cash generationThe Apex TimesBusinessAMD edges into a niche AI-networking layer as new GPU transport work targets efficiencyThe Apex TimesBusinessBefore AMD’s 137% surge, market focus shifted to AI accelerator demand and the MI450 launch narrativeThe Apex TimesBusinessAMD’s Q3 2026 Earnings Set for Early Next Month, With Analysts Looking for Double-Digit Bottom-Line GrowthThe Apex TimesBusinessBYD versus Tesla: A stock comparison that goes beyond electric-vehicle salesThe Apex TimesBusinessWall Street Sells Off as S&P 500 and Nasdaq Slip Below Key Levels, Turning Meta Earnings Into a Test for AI StocksThe Apex TimesBusinessAlphabet shares draw attention as Google and Unity move toward AI-powered game creationThe Apex TimesBusinessElon Musk Praises Jensen Huang as SpaceX and NVIDIA Push AI Data Centers for SpaceThe Apex TimesBusinessBroadcom’s AI XPUs become a focal point as investors weigh the company’s growth outlookThe Apex TimesBusinessMeta’s “Second Act” Pitch Gains Steam as Investors Focus on Muse and AI MomentumThe Apex TimesBusinessNetflix trims about 6% of staff, cutting roughly 1,000 jobs in biggest layoff round in four yearsThe Apex TimesBusinessNorthrop Grumman’s LITEF unit signs long-term inertial reference systems deal for Vertical Aerospace’s Valo eVTOLThe Apex TimesBusinessGeneral Dynamics investors weigh valuation questions as CEO succession talk reshapes attention on cash generationThe Apex TimesBusinessAMD edges into a niche AI-networking layer as new GPU transport work targets efficiencyThe Apex TimesBusinessBefore AMD’s 137% surge, market focus shifted to AI accelerator demand and the MI450 launch narrativeThe Apex TimesBusinessAMD’s Q3 2026 Earnings Set for Early Next Month, With Analysts Looking for Double-Digit Bottom-Line GrowthThe Apex TimesBusinessBYD versus Tesla: A stock comparison that goes beyond electric-vehicle salesThe Apex TimesBusinessWall Street Sells Off as S&P 500 and Nasdaq Slip Below Key Levels, Turning Meta Earnings Into a Test for AI StocksThe Apex TimesBusinessAlphabet shares draw attention as Google and Unity move toward AI-powered game creationThe Apex TimesBusinessElon Musk Praises Jensen Huang as SpaceX and NVIDIA Push AI Data Centers for SpaceThe Apex TimesBusinessBroadcom’s AI XPUs become a focal point as investors weigh the company’s growth outlookThe Apex TimesBusinessMeta’s “Second Act” Pitch Gains Steam as Investors Focus on Muse and AI MomentumThe Apex TimesBusinessNetflix trims about 6% of staff, cutting roughly 1,000 jobs in biggest layoff round in four yearsThe Apex TimesBusinessNorthrop Grumman’s LITEF unit signs long-term inertial reference systems deal for Vertical Aerospace’s Valo eVTOLThe Apex TimesBusinessGeneral Dynamics investors weigh valuation questions as CEO succession talk reshapes attention on cash generationThe Apex TimesBusinessAMD edges into a niche AI-networking layer as new GPU transport work targets efficiencyThe Apex TimesBusinessBefore AMD’s 137% surge, market focus shifted to AI accelerator demand and the MI450 launch narrativeThe Apex TimesBusinessAMD’s Q3 2026 Earnings Set for Early Next Month, With Analysts Looking for Double-Digit Bottom-Line GrowthThe Apex TimesBusinessBYD versus Tesla: A stock comparison that goes beyond electric-vehicle salesThe Apex TimesBusinessWall Street Sells Off as S&P 500 and Nasdaq Slip Below Key Levels, Turning Meta Earnings Into a Test for AI StocksThe Apex TimesBusinessAlphabet shares draw attention as Google and Unity move toward AI-powered game creationThe Apex TimesBusinessElon Musk Praises Jensen Huang as SpaceX and NVIDIA Push AI Data Centers for SpaceThe Apex TimesBusinessBroadcom’s AI XPUs become a focal point as investors weigh the company’s growth outlookThe Apex TimesBusinessMeta’s “Second Act” Pitch Gains Steam as Investors Focus on Muse and AI MomentumThe Apex TimesBusinessNetflix trims about 6% of staff, cutting roughly 1,000 jobs in biggest layoff round in four yearsThe Apex TimesBusinessNorthrop Grumman’s LITEF unit signs long-term inertial reference systems deal for Vertical Aerospace’s Valo eVTOLThe Apex TimesBusinessGeneral Dynamics investors weigh valuation questions as CEO succession talk reshapes attention on cash generationThe Apex Times
Back to front
Merck and Moderna report Phase 3 topline gains for INTerpath-001 in resected stage IIB-IV melanoma
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 6:54 AM EDT

Merck and Moderna report Phase 3 topline gains for INTerpath-001 in resected stage IIB-IV melanoma

The companies said their Phase 3 trial combining Moderna’s intismeran autogene with Merck’s KEYTRUDA met key recurrence and distant metastasis endpoints in patients whose tumors were completely removed.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Merck and Moderna said they have generated positive topline results from their Phase 3 INTerpath-001 trial testing a combination therapy in patients with completely resected stage IIB-IV melanoma. The treatment pairs Moderna’s intismeran autogene with Merck’s KEYTRUDA, an immunotherapy designed to help the immune system recognize and attack cancer cells.

In a joint announcement dated August 19, 2026, the companies said the study met two key efficacy endpoints: recurrence-free survival (RFS) and distant metastasis-free survival (DMFS). RFS measures the length of time patients live without the melanoma returning, while DMFS tracks time until cancer spreads to distant sites.

The trial population includes people with stage IIB-IV melanoma whose tumors were completely removed, placing the study in the adjuvant setting. In adjuvant trials, sponsors generally focus on whether a therapy can reduce the risk of recurrence after surgery, particularly in higher-risk stages where microscopic disease may remain.

Merck noted in the release that it is known as MSD outside the United States and Canada, reflecting how the companies brand the same corporate entity across markets. Moderna trades on the Nasdaq under the ticker MRNA, while Merck trades as MRK on the NYSE.

KEYTRUDA is a well-established anti-PD-1 therapy. In combination with a next-generation messenger RNA (mRNA)-based approach, INTerpath-001 reflects a broader industry strategy of pairing immunotherapies with individualized or immune-modulating components to improve outcomes for patients at high risk of recurrence.

For Moderna, the readout is another attempt to translate mRNA biology into oncology endpoints that matter clinically, beyond early-stage safety indicates. For Merck, the results provide data supporting the expansion of KEYTRUDA-based regimens into earlier and higher-risk disease settings, where preventing relapse is often a primary goal.

The companies’ announcement, as presented in the post, does not include additional details such as hazard ratios, p-values, median follow-up duration, or whether any specific subgroup results were emphasized. It also does not lay out safety findings, including the incidence of immune-related adverse events, which would typically be critical for interpreting a Phase 3 topline release.

Going forward, investors and clinicians will likely look for the full Phase 3 data set, including safety, the magnitude of benefit for RFS and DMFS, and any descriptive details about dosing and patient characteristics. A subsequent presentation or regulatory filing could further clarify how the combination compares with standard adjuvant options and whether the results persist across longer follow-up.

Why It Matters

  • Meeting RFS and DMFS in a resected melanoma population suggests the regimen may reduce both relapse risk and spread to distant sites, key outcomes in adjuvant oncology.
  • KEYTRUDA is often evaluated across multiple tumor settings, and a positive Phase 3 readout in stage IIB-IV resected melanoma could broaden the therapy’s potential use beyond advanced disease.
  • For Moderna, the results are a tangible validation point for an mRNA-based partner in oncology Phase 3 development, though the market will still need full efficacy and safety details.
  • The next catalyst will likely be more granular Phase 3 reporting, because topline endpoint success alone does not establish the level of clinical benefit or tolerability for routine use.

Sources

Key Facts

  • Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial in completely resected stage IIB-IV melanoma.
  • The combination tested in the study is Moderna’s intismeran autogene plus Merck’s KEYTRUDA.
  • The companies said the trial met recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) key endpoints.
  • The release frames the study in an adjuvant context, targeting patients after complete surgical removal of melanoma.
  • The announcement did not provide, in the available post, the magnitude of benefit (for example, hazard ratios) or detailed safety data.

Healthcare Related

Merck and Moderna report Phase 3 topline gains for INTerpath-001 in resected stage IIB-IV melanoma | The Apex Times